STOCK TITAN
  1. Home
  2. Sec-filings
  3. CPIX
  4. [Form 4] CUMBERLAND PHARMACEUTICALS INC Insider Trading Activity

CPIX Insider Buys: A.J. Kazimi Raises Stake to 5.70M Shares in Sept

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

A.J. Kazimi, Chairman and CEO of Cumberland Pharmaceuticals Inc. (CPIX), reported a series of open-market purchases executed under a Rule 10b5-1 trading plan adopted on November 14, 2024. The reported transactions occurred between September 2, 2025 and September 30, 2025, with incremental buys at prices ranging from $3.05 to $3.60. Following the transactions, the filing shows beneficial ownership of 5,700,284 shares. The Form 4 was signed by an attorney-in-fact, John Hamm, on October 3, 2025. The filing identifies the reporting person as a Director, 10% owner, and Chairman and CEO.

Positive

  • Insider purchases executed by the CEO under a Rule 10b5-1 plan
  • Beneficial ownership increased to 5,700,284 shares
  • Trades were executed across multiple dates (Sept 2–30, 2025), showing systematic accumulation

Negative

  • None.

Insights

TL;DR: CEO A.J. Kazimi executed repeated purchases under a Rule 10b5-1 plan, raising beneficial ownership to 5,700,284 shares.

The filing documents systematic, small-lot acquisitions from September 2–30, 2025 under a pre-established Rule 10b5-1 trading plan adopted on November 14, 2024. Using a plan is a common compliance mechanism that permits scheduled trades despite insider status.

Transaction prices disclosed range from $3.05 to $3.60, indicating the buys were executed across varying market prices rather than a single block trade. The Form 4 lists final beneficial ownership as 5,700,284 shares and is signed by an attorney-in-fact on October 3, 2025.

Insider KAZIMI A J
Role Chairman and CEO
Type Security Shares Price Value
L Common Stock 13 $3.12 $40.56
L Common Stock 13 $3.14 $40.82
L Common Stock 12 $3.05 $36.60
L Common Stock 12 $3.10 $37.20
L Common Stock 12 $3.10 $37.20
L Common Stock 12 $3.21 $38.52
L Common Stock 12 $3.29 $39.48
L Common Stock 12 $3.34 $40.08
L Common Stock 12 $3.31 $39.72
L Common Stock 12 $3.38 $40.56
L Common Stock 12 $3.50 $42.00
L Common Stock 12 $3.50 $42.00
L Common Stock 12 $3.54 $42.48
L Common Stock 12 $3.41 $40.92
L Common Stock 12 $3.39 $40.68
L Common Stock 12 $3.43 $41.16
L Common Stock 12 $3.41 $40.92
L Common Stock 12 $3.60 $43.20
L Common Stock 12 $3.60 $43.20
L Common Stock 12 $3.58 $42.96
L Common Stock 12 $3.54 $42.48
Holdings After Transaction: Common Stock — 5,700,284 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
KAZIMI A J
(Last) (First) (Middle)
1600 WEST END AVE.
SUITE 1300
(Street)
NASHVILLE TN 37203
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Chairman and CEO
3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/02/2025 L V 12(1) A $3.54 5,700,042 D
Common Stock 09/03/2025 L V 12(1) A $3.58 5,700,054 D
Common Stock 09/04/2025 L V 12(1) A $3.6 5,700,066 D
Common Stock 09/05/2025 L V 12(1) A $3.6 5,700,078 D
Common Stock 09/08/2025 L V 12(1) A $3.41 5,700,090 D
Common Stock 09/09/2025 L V 12(1) A $3.43 5,700,102 D
Common Stock 09/10/2025 L V 12(1) A $3.39 5,700,114 D
Common Stock 09/11/2025 L V 12(1) A $3.41 5,700,126 D
Common Stock 09/12/2025 L V 12(1) A $3.54 5,700,138 D
Common Stock 09/15/2025 L V 12(1) A $3.5 5,700,150 D
Common Stock 09/16/2025 L V 12(1) A $3.5 5,700,162 D
Common Stock 09/17/2025 L V 12(1) A $3.38 5,700,174 D
Common Stock 09/18/2025 L V 12(1) A $3.31 5,700,186 D
Common Stock 09/19/2025 L V 12(1) A $3.34 5,700,198 D
Common Stock 09/22/2025 L V 12(1) A $3.29 5,700,210 D
Common Stock 09/23/2025 L V 12(1) A $3.21 5,700,222 D
Common Stock 09/24/2025 L V 12(1) A $3.1 5,700,234 D
Common Stock 09/25/2025 L V 12(1) A $3.1 5,700,246 D
Common Stock 09/26/2025 L V 12(1) A $3.05 5,700,258 D
Common Stock 09/29/2025 L V 13(1) A $3.14 5,700,271 D
Common Stock 09/30/2025 L V 13(1) A $3.12 5,700,284 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.
Remarks:
A.J. Kazimi by /s/ John Hamm as attorney-in-fact 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Cumberland Pharmaceuticals (CPIX) insider A.J. Kazimi report on Form 4?

The Form 4 reports multiple open-market purchases between Sept 2 and Sept 30, 2025 under a Rule 10b5-1 plan, bringing beneficial ownership to 5,700,284 shares.

How many shares does A.J. Kazimi beneficially own after the reported transactions?

The filing reports 5,700,284 shares beneficially owned following the reported purchases.

What price range did the insider purchases occur at?

Reported purchase prices in the filing range from $3.05 to $3.60 per share.

Were these trades part of a prearranged plan?

Yes. The purchases were made automatically pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.

Who signed the Form 4 and when was it filed?

The Form 4 was signed by attorney-in-fact John Hamm and dated October 3, 2025.